Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.
Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.
Altamira is actively engaged in three primary areas:
- RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
- Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
- Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.
Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.
In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.
Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.
Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.
Altamira Therapeutics (NASDAQ:CYTO) will participate in the 4th Annual RAS-Targeted Drug Development Summit from September 26-28, 2022, in Boston. Chief Scientific Officer Samuel Wickline, MD, will present on the OligoPhore platform for targeting KRAS-driven cancers. The summit aims to unite over 300 experts focused on therapeutic advancements for RAS-mutant cancers. Altamira has two RNA-based programs: AM-401 for KRAS-driven cancers and AM-411 for rheumatoid arthritis, emphasizing a unique approach that enhances delivery of RNA therapeutics to cancer cells.
Altamira Therapeutics (NASDAQ:CYTO) is shifting its focus to RNA therapeutics while planning to divest or spin off its legacy assets, including Bentrio and AM-125 nasal sprays. In H1 2022, Bentrio generated $1.3 million in revenue. The company aims to commercialize Bentrio globally through partnerships, with significant interest in the U.S. and European markets. Altamira is also moving forward with AM-125's development and preparing for an IND filing by Q4 2022. The company is making strides in RNA delivery technology, with promising results in preclinical studies.
Altamira Therapeutics (NASDAQ:CYTO) is transforming its business by focusing on RNA therapeutics, addressing unmet medical needs. CEO Thomas Meyer highlighted the company's strategy to out-license projects in oncology and rheumatoid arthritis, leveraging its patented RNA delivery technology. Plans for divesting legacy programs are underway, with milestones expected to drive growth. The company aims to establish itself as a pure RNA therapeutics player, enhancing its market position through innovative solutions.
Altamira Therapeutics (NASDAQ:CYTO) announces the continuation of enrollment in the COVAMID trial, increasing the participant count from 136 to 160 to enhance statistical power. The top-line results are anticipated by early Q4-22. The trial evaluates the efficacy of Bentrio, a drug-free nasal spray for COVID-19, in a randomized placebo-controlled study. Bentrio aims for label expansion into viral infections in key markets including the US and EU. The interim analysis indicated a higher standard deviation than expected, prompting the increase in subjects for rigorous efficacy testing.
Altamira Therapeutics (NASDAQ:CYTO) announced a peer-reviewed study confirming its OligoPhore delivery platform's potential in RNA treatments for osteoarthritis. Conducted by a Shanghai-based group, the study demonstrated that knockdown of the JMJD3 gene using OligoPhore significantly mitigated joint degeneration in an animal model. This innovative therapy targets inflammation specifically in the joints, offering a promising approach to treat osteoarthritis, which currently lacks disease-modifying treatments. The research emphasizes the role of OligoPhore in enhancing RNA therapeutic efficacy.
Altamira Therapeutics (NASDAQ:CYTO) has launched a new drug development program, AM-411, targeting rheumatoid arthritis (RA) utilizing its proprietary OligoPhore delivery platform. This initiative follows encouraging animal study results and aims to out-license AM-411 in the future. RA affects approximately 1.3 million adults in the US and is projected to be a $62.9 billion market by 2027. AM-411 demonstrated effective inflammation suppression in preclinical models, focusing on the NF-κB pathway, which is crucial in RA. The company also plans to advance its other project, AM-401, for KRAS-driven cancers.
Altamira Therapeutics (NASDAQ: CYTO) announced a peer-reviewed study published in Pharmaceutics that demonstrates the potential of cell-penetrating peptides (CPPs) in mRNA-based cancer therapies. The study highlighted the superior uptake and transfection capacity of Altamira's SemaPhore platform compared to cationic CPPs. The results indicate that SemaPhore-mRNA complexes enhance protein expression within cancer cells, showcasing an advantage over traditional lipid-based nanoparticles. Dr. Samuel Wickline emphasized SemaPhore's ability for effective systemic delivery to extrahepatic targets, relevant for various therapeutic areas.
Altamira Therapeutics (NASDAQ:CYTO) announced the publication of a peer-reviewed article in Biomaterials Advances that showcases the effectiveness of its patented RNA delivery platform in mitigating abdominal aortic aneurysm (AAA) progression and rupture in a murine model. The study, conducted independently by researchers at Washington University, identified NF-κB p50 as a key target for drug design. With AAA leading to approximately 15,000 deaths annually in the U.S., the findings highlight the potential of Altamira's OligoPhore platform as a non-surgical treatment for this severe condition.
Altamira Therapeutics (NASDAQ:CYTO) has announced the signing of marketing and distribution agreements for its Bentrio™ nasal spray in Pakistan and Egypt. Partnering with deKhon Global in Pakistan and Vie Pharma in Egypt, the company taps into significant markets with populations of 242 million and 106 million, respectively. These agreements expand Bentrio's global reach beyond Europe, Asia, and the Middle East, enhancing its distribution network. Bentrio is a drug-free product aimed at providing protection against airborne viruses and allergens, already cleared for allergic rhinitis treatment in the US.
Altamira Therapeutics (NASDAQ:CYTO) has received FDA 510(k) clearance for its nasal spray, Bentrio Allergy Blocker, aimed at treating allergic rhinitis (hay fever). This approval allows the company to market Bentrio in the U.S., the largest OTC market for consumer health products. Bentrio works by creating a protective gel barrier in the nasal cavity to alleviate symptoms caused by allergens. Altamira anticipates that Bentrio will contribute significantly to its revenues over the next few years, with plans to launch through major e-commerce platforms and engage with distribution partners.
FAQ
What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What areas of therapeutics does Altamira Therapeutics focus on?
What are the main products of Altamira Therapeutics?
Where is Altamira Therapeutics headquartered?
What is the stock symbol for Altamira Therapeutics?
What recent achievements has Altamira Therapeutics made in RNA therapeutics?
What stage are the inner ear disorder treatments in?
How does the OligoPhore™ platform work?
What are the recent clinical trial results for Bentrio™?
What is the significance of recent financial reclassifications for Altamira?